Peptide receptor therapies in neuroendocrine tumors. (Q37563878)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636207 AND SRC:MED&resulttype=core&format=json

3 February 2020

review article

1 reference

title

Peptide receptor therapies in neuroendocrine tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636207 AND SRC:MED&resulttype=core&format=json

3 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636207 AND SRC:MED&resulttype=core&format=json

3 February 2020

author name string

L Bodei

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636207 AND SRC:MED&resulttype=core&format=json

3 February 2020

C M Grana

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636207 AND SRC:MED&resulttype=core&format=json

3 February 2020

M Cremonesi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636207 AND SRC:MED&resulttype=core&format=json

3 February 2020

A Signore

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636207 AND SRC:MED&resulttype=core&format=json

3 February 2020

R A Dierckx

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636207 AND SRC:MED&resulttype=core&format=json

3 February 2020

G Paganelli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636207 AND SRC:MED&resulttype=core&format=json

3 February 2020

publication date

1 April 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636207 AND SRC:MED&resulttype=core&format=json

Journal of Endocrinological Investigation

3 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636207 AND SRC:MED&resulttype=core&format=json

3 February 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636207 AND SRC:MED&resulttype=core&format=json

3 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636207 AND SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

360-369

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636207 AND SRC:MED&resulttype=core&format=json

The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept

3 February 2020

cites work

1 reference

The neuroendocrine concept today

21 January 2018

2 references

21 January 2018

12 December 2020

Neuroendocrine tumours

1 reference

Gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours.

21 January 2018

1 reference

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

21 January 2018

1 reference

Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography

21 January 2018

1 reference

68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors

21 January 2018

1 reference

Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

21 January 2018

1 reference

Therapeutic options for gastrointestinal carcinoids

21 January 2018

1 reference

Endocrine tumours of the gastrointestinal tract. Surgical treatment of neuroendocrine metastases

21 January 2018

1 reference

Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours

21 January 2018

1 reference

Radiofrequency thermal ablation of metastatic neuroendocrine tumors in the liver

21 January 2018

1 reference

High-intensity focused ultrasound: current potential and oncologic applications

21 January 2018

1 reference

Chemotherapy for gastro-enteropancreatic endocrine tumours

21 January 2018

1 reference

Neuroendocrine tumors. Biotherapy

21 January 2018

1 reference

The pathophysiological consequences of somatostatin receptor internalization and resistance

21 January 2018

1 reference

Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?

21 January 2018

1 reference

Molecular targeted therapy for neuroendocrine tumors

21 January 2018

1 reference

Cell biology. A last GASP for GPCRs?

21 January 2018

1 reference

21 January 2018

1 reference

The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?

21 January 2018

1 reference

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

21 January 2018

1 reference

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

21 January 2018

1 reference

Radionuclide therapy with iodine-125 and other auger-electron-emitting radionuclides: experimental models and clinical applications

21 January 2018

1 reference

Improved radiotracing of oxytocin receptor-expressing tumours using the new [111In]-DOTA-Lys8-deamino-vasotocin analogue

21 January 2018

1 reference

In vivo and in vitro detection of dopamine d2 receptors in uveal melanomas

21 January 2018

1 reference

Dopamine receptor expression and function in corticotroph ectopic tumors.

21 January 2018

1 reference

Cabergoline plus lanreotide for ectopic Cushing's syndrome

21 January 2018

1 reference

Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.

21 January 2018

1 reference

Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation.

21 January 2018

1 reference

Novel subtype specific and universal somatostatin analogues: clinical potential and pitfalls

21 January 2018

1 reference

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

21 January 2018

1 reference

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

21 January 2018

1 reference

Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".

21 January 2018

1 reference

Clinical radiation nephropathy

21 January 2018

1 reference

Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy

21 January 2018

1 reference

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

21 January 2018

1 reference

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

21 January 2018

1 reference

Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group

21 January 2018

1 reference

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

21 January 2018

1 reference

Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.

21 January 2018

1 reference

Is CD20 the only target available for radionuclide therapy in lymphoproliferative disorders?

21 January 2018

1 reference

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model.

21 January 2018

1 reference

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

21 January 2018

1 reference

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate

21 January 2018

1 reference

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

Peptide receptor expression in GEP-NET.

21 January 2018

1 reference

SPECT imaging with 111In-octreotide for the localization of pancreatic insulinoma

21 January 2018

1 reference

12 December 2020

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group

1 reference

12 December 2020

New advances in peptide receptor radionuclide therapy.

1 reference

12 December 2020

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

1 reference

12 December 2020

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate

1 reference

12 December 2020

Peptide receptor imaging and therapy

1 reference

12 December 2020

Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.

1 reference

12 December 2020

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

1 reference

12 December 2020

The radiobiology of conventional radiotherapy and its application to radionuclide therapy

1 reference

12 December 2020

Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

1 reference

12 December 2020

Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo

1 reference

12 December 2020

Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy

1 reference

12 December 2020

Candidates for peptide receptor radiotherapy today and in the future.

1 reference

12 December 2020

Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC

1 reference

12 December 2020

Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin

1 reference

12 December 2020

Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship

1 reference

12 December 2020

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

12 December 2020

Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy

1 reference

12 December 2020

Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy

1 reference

12 December 2020

BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide

1 reference

12 December 2020

Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.

1 reference

12 December 2020

High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects

1 reference

12 December 2020

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

1 reference

12 December 2020

New trends in peptide receptor radioligands

1 reference

12 December 2020

Yttrium-90 DOTATOC: first clinical results

1 reference

12 December 2020

Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients

1 reference

12 December 2020

Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?

1 reference

12 December 2020

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

1 reference

12 December 2020

D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake

1 reference

12 December 2020

177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.

1 reference

12 December 2020

Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors

1 reference

12 December 2020

Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid)

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03345728

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19636207 AND SRC:MED&resulttype=core&format=json

3 February 2020

1 reference